Registry for Esophageal and Gastroesophageal Junction Cancer

This study is a registry, which means it's collecting information to better understand standard treatments for esophageal cancer and gastroesophageal junction (GEJ) cancer. Researchers want to learn how effective different treatment options are. You might be able to join if you are newly diagnosed with stage IV adenocarcinoma of the esophagus or GEJ that has spread to other parts of your body (OMD), such as lymph nodes, liver, or lung. The study will measure how long people live without their cancer getting worse (Progression Free Survival) at one year. The study is currently unclear about its status and plans to include 50 participants.

Study design: This is an observational study, meaning researchers will collect information without giving specific treatments. It aims to enroll 50 participants.
What's involved: Participants will complete two questionnaires: the EORTC QLQ-C30, which covers general health and quality of life, and the QLQ-OGS25, which focuses on symptoms specific to esophageal, GEJ, or gastric cancer.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint, Progression Free Survival, is measured at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Registry for Esophageal and Gastroesophageal Junction Cancer

Recruiting

Not specifiedAges 18+Observational

Memorial Sloan Kettering Cancer Center

~50 participants

Updated 2026-05-22 on ClinicalTrials.gov

What's tested:EORTC QLQ-C30 questionnaireQLQ-OGS25 questionnaire

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Progression Free Survival

Measured over 1 year

Conditions

Gastroesophageal-junction Cancer

Esophageal Cancer

NCT06558786

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New Yorkstudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Daniela Molena, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Daniela Molena, MD

[email protected]

212-639-3870

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Newly diagnosed stage IV adenocarcinoma of the esophagus or GEJ with OMD at the time of diagnosis, defined as the following:

Retroperitoneal lymph nodes (e.g., para-aortal, intra-aorto-caval, parapancreatic, or mesenterial lymph node)

Liver

Lung

Extra-abdominal lymph nodes (e.g., supraclavicular or cervical lymph nodes)

Adrenal gland

Unilateral or bilateral ovarian metastases (in the absence of gross or microscopic peritoneal disease \[positive cytology\])

Bone

≤2 sites of disease (excluding the primary tumor and regional lymph nodes)

≤3 tumors within each organ system

≤5 metastases

All nonregional lymph nodes (including cervical, supraclavicular, and retroperitoneal nodal disease) are considered 1 discrete lesion

Satellite lesions in the primary esophageal malignancy, such as skipped esophageal primaries, are not considered metastatic sites

All sites of disease must be amenable to complete local therapy after systemic therapy, according to the treating physician. Treatment modalities include:

Surgery

Definitive chemoradiation

Stereotactic radiation

Ablation or similar techniques (e.g., irreversible electroporation)

Age ≥18 years

Exclusion

Presence of metastases, at the time of diagnosis, to the following:

Peritoneum, including positive peritoneal lavage (on the basis of baseline diagnostic laparoscopy to rule out gross disease and positive peritoneal lavage cytology; laparoscopy may be omitted for patients in whom all sites of disease are above the diaphragm)

Malignant pleural effusion

Brain metastases or leptomeningeal disease

Other sites not specifically noted must be reviewed and approved by the PIs

Any site of disease that is not amenable to definitive local therapy

Unfit for best systemic therapy

Metachronous OMD

Secondary primary cancer, with the exclusion of basal cell carcinoma of the skin

Pregnant, lactating, or intending to become pregnant

Unwilling to provide informed consent

What this trial measures

Progression Free Survival1 year
Estimate 12-month PFS among patients who undergo definitive local therapy after induction chemotherapy

Trialytics